Protagonist Therapeutics (PTGX) Tops Q3 EPS by 1c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q3 EPS of ($0.62), $0.01 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $4.71 million versus the consensus estimate of $4.51 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• Pacific Booker Minerals Inc. Adopts Advance Notice Policy for Director Elections